EFFECTS OF VITAMIN D ANALOGS ON ERYTHROPOIESIS-STIMULATING AGENT DASAGE AND SECONDARY ANEMIA IN HEMODIALYSIS PATIENTS.
To investigate the effects of Vitamin D Analogs, paricalcitol and alphacalcidol, on hemoglobin levels and erythropoietin-stimulating agents' dosage in hemodialysis patients with chronic renal failure. A total of 310 patients under hemodialysis treatment for chronic renal failure were included in this retrospective multicenter study. Data on serum parathormone and hemoglobin levels, erythropoietin-stimulating agents' doses, C-reactive protein, calcium and phosphate levels were collected from medical records to comparatively evaluate paricalcitol, alphacalcidol and no treatment groups. Apart from significantly higher levels for hematocrit in patients treated with paricalcitol compared to pre-treatment values (32.3(3.8) vs. 34.1(3.1) p=0.007), pre-treatment and post-treatment values for biochemical parameters were similar in paricalcitol and alphacalcidol groups including ESA dose. A significant increase in parathormone levels (p=0.000 for each) while a significant decrease in calcium (p=0.003 and 0.040, respectively), Hb (p=0.001 and 0.009, respectively) and hematocrit (p=0.001 and 0.021, respectively) levels were determined in paricalcitol and alphacalcidol treated patients compared with untreated patients. Also, phosphate levels in alphacalcidol treated patients were significantly higher (p=0.018) than untreated patients. Our findings revealed insufficient suppression of parathormone levels and there of lower hemoglobin and hematocrit levels, but similar ESA dosage among CRF patients treated with Vitamin D analogs compared with untreated patients.
Sakarya University Medicine Faculty, Department of Internal Medicine, Department of Internal Medicine, Division of Nephrology, Sakarya; Rize Fındıklı State Hospital Rize, Department of Internal Medicine, Turkey.
C
C
Varim
Sakarya University Medicine Faculty, Department of Internal Medicine, Department of Internal Medicine, Division of Nephrology, Sakarya; Rize Fındıklı State Hospital Rize, Department of Internal Medicine, Turkey.
S
S
Sipahi
Sakarya University Medicine Faculty, Department of Internal Medicine, Department of Internal Medicine, Division of Nephrology, Sakarya; Rize Fındıklı State Hospital Rize, Department of Internal Medicine, Turkey.
S
S
Yaylaci
Sakarya University Medicine Faculty, Department of Internal Medicine, Department of Internal Medicine, Division of Nephrology, Sakarya; Rize Fındıklı State Hospital Rize, Department of Internal Medicine, Turkey.
T
T
Kaya
Sakarya University Medicine Faculty, Department of Internal Medicine, Department of Internal Medicine, Division of Nephrology, Sakarya; Rize Fındıklı State Hospital Rize, Department of Internal Medicine, Turkey.
A
A
Nalbant
D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004872:Ergocalciferols / Q000627:therapeutic use*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D006435:Renal Dialysis; D012189:Retrospective Studies
D004872:Ergocalciferols; D006397:Hematinics; D006454:Hemoglobins; D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; C084656:paricalcitol; C008088:alfacalcidol